RECORDATI SUBMITS NEW DRUG APPLICATION FOR ISTURISA IN JAPAN - Seite 3

For further information:

Recordati website:  www.recordati.com

Investor Relations                                                                         Media Relations                             
Marianne Tatschke                                                                       Studio Noris Morano                                                   
(39)0248787393                                                                              (39)0276004736, (39)0276004745
e-mail: [e-mail]                                   e-mail: [e-mail]
                                                                             

Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company’s control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company’s activities and are not intended to indicate the advisability of administering any product in any particular instance.

Attachment

• Isturisa filing Japan